<em>Targeted Oncology</em>™ will launch its third “Expert Perspective: Virtual Tumor Board” on Monday, September 24. Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.
Targeted Oncology™, a print and digital resource that offers content and expert opinions on standard and emerging treatments in the oncology field, will launch its third “Expert Perspective: Virtual Tumor Board” on Monday, September 24. Each Virtual Tumor Board is a video-editorial discussion that features key opinion leaders from a specific oncological field considering options for treating patients based on case scenarios. This episode will focus on multiple myeloma.
“We look forward to launching the next Virtual Tumor Board on September 24,” said Michael J. Hennessy Jr., president of MJH Associates Inc., parent company ofTargeted Oncology. “Expert leaders will really get the chance to dive in to several patient’s cases and truly help make a difference in the multiple myeloma community.”
The Virtual Tumor Board will feature experts providing in-depth analysis on four patients with multiple myeloma and sharing information on their diagnoses, pathology results and treatment strategies from a collaborative medical setting based on recent data and clinical trial findings. With these cases, the multidisciplinary team discuss high-risk cytogenetics, maintenance therapy, the possibility for CAR T-cell therapy, and more for specific instances of multiple myeloma.
The key opinion leaders participating in this Virtual Tumor Board are:
About Targeted Oncology™
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
FDA Enforces Partial Hold on Trial of Seclidemstat in MDS/CMML
July 16th 2024Following the report of a serious and unexpected grade 4 adverse effect, a partial clinical hold has been placed on the phase 1 trial evaluating seclidemstat with azacitidine in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Read More